PT  - JOURNAL ARTICLE
AU  - YUKI MINAGAWA
AU  - KOUSUKE ISHINO
AU  - RYUICHI WADA
AU  - MITSUHIRO KUDO
AU  - ZENYA NAITO
AU  - TOSHIYUKI TAKESHITA
AU  - RYUJI OHASHI
TI  - High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear-cell Carcinoma
AID  - 10.21873/anticanres.14576
DP  - 2020 Oct 01
TA  - Anticancer Research
PG  - 5631--5639
VI  - 40
IP  - 10
4099  - http://ar.iiarjournals.org/content/40/10/5631.short
4100  - http://ar.iiarjournals.org/content/40/10/5631.full
SO  - Anticancer Res2020 Oct 01; 40
AB  - Background/Aim: DNA damage response (DDR), wherein p21 is a cell fate determinant, is a potential cancer therapeutic target. Molecular expression during DDR was explored in ovarian clear-cell carcinoma (CCC). Materials and Methods: CHK1, CHK2, TP53 and p21 expression in DDR was examined using immunostaining in surgical sections of CCC (n=22). Molecular alterations in two types of CCC cell lines, JHOC-5 and JHOC-9, were investigated using western blot analysis. Results: Expression of DDR-associated molecules was noted in most patients. While high p21 expression was found in half of the patients, the remaining patients exhibited low p21 expression. Treatment with UC2288, a p21 inhibitor, attenuated proliferation of both cell lines, more prominently in JHOC-9, resulting in reduced viability and subsequent apoptosis. Conclusion: p21 Inhibitor induced cell death in cells with high p21 expression, suggesting that p21 suppression can be a therapeutic strategy to treat patients with CCC.